Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Increases By 188.0%

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw a significant growth in short interest in August. As of August 15th, there was short interest totaling 28,800 shares, agrowthof188.0% from the July 31st total of 10,000 shares. Based on an average trading volume of 24,800 shares, the short-interest ratio is currently 1.2 days. Based on an average trading volume of 24,800 shares, the short-interest ratio is currently 1.2 days.

Inventiva Price Performance

Inventiva stock opened at $5.57 on Friday. Inventiva has a one year low of $1.53 and a one year high of $6.50. The company’s fifty day moving average price is $3.90 and its two-hundred day moving average price is $3.46.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IVA shares. HC Wainwright started coverage on Inventiva in a research note on Wednesday. They set a “buy” rating and a $20.00 target price for the company. Piper Sandler started coverage on Inventiva in a research note on Wednesday, August 27th. They set an “overweight” rating and a $26.00 target price for the company. Finally, Guggenheim raised their target price on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Inventiva has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Institutional Investors Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Creative Planning purchased a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.